Hyperparathyroidism healing in patients treated for hyperaldosteronism: three cases
نویسندگان
چکیده
منابع مشابه
Unusual presentation of primary hyperparathyroidism: report of three cases
BACKGROUND Primary hyperparathyroidism is an endocrinopathic condition characterized by hypersecretion of parathyroid hormone. Excess parathyroid hormone results in an altered state of osseous metabolism involving bone resorption and tissue change known as osteitis fibrosa cystica, which is the end stage of primary hyperparathyroidism. Osteitis fibrosa cystica is associated with the development...
متن کاملBehcet\'s Disease (Introduction of Three Cases Treated With Immunosuppressor Drugs)
CONCLUSION Apres avoir discute l'etiologie et la pathogenie de la maladie de Beh<;et, nous avons essaye de traiter trois patients atteints de cette maladie, par Jes immunosuppresseurs. Les resultats ont etc les suivants: I -Dans un cas le resultat est excellent; Ia vision est presque normalisee. 2 -Le deuxieme cas montre une amelioration partielle de la vision depuis 3 ans, sans aucune...
متن کاملIntensification of Anemia by Secondary Hyperparathyroidism in Hemodialysis Patients
The excessive amounts of parathyroid hormone in secondary hyperparathyroidism (SHPTH) is suggested to interfere with normal erythropoiesis. In SHPTH, during chronic renal failure, due to the impairment of erythropoietin synthesis, this effect is more pronounced. In the present study the role of secondary hyperparathyroidism in the severity of anemia was evaluated in hemodialysis patients (n=3...
متن کاملThrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
BACKGROUND Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) is a rare but severe complication, with a fulminant clinical onset and a possibly life-threatening outcome that may occur years after a well-tolerated treatment with IFN. Most patients evolve rapidly to advanced ch...
متن کاملGastrointestinal Perforation in Patients with Metastatic Colorectal Cancer treated with Bevacizumab (Avastin) Three Cases Report
approved by the U.S. Food and Drug Administration in February 2004 and the European Medicines Agency in January 2005 for use in metastatic colorectal cancer (mCRC). In a phase III clinical trial it was shown to improve survival and progression-free survival and an increased response rate as compared to a chemotherapy (IFL) regimen containing bolus fluorouracil (5-FU), leucovorin (LV), and irino...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endocrine Abstracts
سال: 2016
ISSN: 1479-6848
DOI: 10.1530/endoabs.41.ep69